- GSK’s vaccine for respiratory syncytial virus proved strongly effective in a large Phase 3 trial, reducing cases of lower respiratory infection in people 60 years and older by 83% when compared to those given a placebo. The U.K. drugmaker gave the results from its trial on Thursday, ahead of an infectious diseases conference next week.
- The shot is the first of its type to have full data from a trial designed to support regulatory approval, with candidates from Pfizer and Johnson & Johnson expected to follow later this year. Pfizer previously released interim data from its trial, indicating the shot was 67% effective against lower-respiratory tract infections, but the company hasn’t disclosed a full analysis.
- After decades of failure, vaccine researchers in recent years figured out how to direct the body’s immune system against a protein specific to RSV, prompting a race to develop the first preventive shot against a virus that causes hundreds of thousands of hospitalizations and tens of thousands of deaths. Moderna, Sanofi and Bavarian Nordic are also testing RSV vaccines.